Evidence map›Paper›PMID 42711843›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Dual-Target Nectin-4/FAP Heterobivalent Probe

Ye Li, Li Sun, Xiaoyu Pan, Shuyi Lin, Dongliang Wang, Jianping Zhang, Fengshuang Qiu, Bin Zhu, Lingzhou Zhao, Fengsheng Zhang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ye Li *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
Li Sun *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
Xiaoyu Pan *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.ORCID https://orcid.org/0009-0007-6687-106X
Shuyi LinDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
Dongliang WangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
Jianping ZhangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
Fengshuang QiuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
Bin ZhuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.ORCID https://orcid.org/0009-0004-4503-9782
Lingzhou ZhaoDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
Fengsheng ZhangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
Liyan BaiDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
Bingxin GuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
Xiaoping XuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.
Shaoli SongDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, P. R. China.ORCID https://orcid.org/0000-0003-2544-7522

Funding

Key Program of National Natural Science Foundation of China U23A20465National Natural Science Foundation of China 12275057National Natural Science Foundation of China 82272305Nuclear Technology R&D Program HNKFHBZ202319Science and Technology Commission of Shanghai Municipality 23DZ2291400Shanghai Collaborative Innovation Project HCXBCY-2024-001Shanghai Oriental Talents Program Youth Project SSF828085
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) features pronounced molecular heterogeneity and poor prognosis, restricting the efficacy of single-targeted strategies. Leveraging the complementary theranostic targets fibroblast activation protein (FAP) and Nectin-4, we designed the novel hetero-bivalent agent FZ-NF-1 for dual targeting. Preclinically, both

Indexed as

FAPIhetero‐bivalent probeNectin‐4theranosticstriple negative breast cancer

Identifiers

PMID42711843
PMCPMC13554372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.